Stock 0RK9 ALLIGATOR BIOSCIENCE AB
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Alligator Bioscience AB London S.E.

Equities

0RK9

SE0000767188

Market Closed - London S.E.
Other stock markets
 15:52:01 17/11/2021 GMT 		5-day change 1st Jan Change
2.508 SEK -66.28% Intraday chart for Alligator Bioscience AB +123.96% +303.28%
05-23 Alligator Bioscience to Present Positive Phase 2 Mitazalimab Data in Pancreatic Cancer at 2024 ASCO Annual Meeting CI
05-21 US FDA Grants Investigational New Drug Clearance for Alligator Bioscience's Late-stage Gastric Cancer Treatment Trial MT

Summary

  • The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • For several months, analysts have been revising their EPS estimates roughly upwards.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

  • With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
ALLIGATOR BIOSCIENCE AB Stock Alligator Bioscience AB
+303.28% 77.57M -
MODERNA, INC. Stock Moderna, Inc.
+43.36% 54.64B
B-
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-5.31% 39.92B
B
LONZA GROUP AG Stock Lonza Group AG
+37.52% 38.82B
A
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+14.75% 26.86B
B-
CELLTRION, INC. Stock Celltrion, Inc.
-12.56% 26.22B
C
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.45% 18.78B
B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.12% 12.21B
B+
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.04% 12.16B
B+
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.04% 11.94B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. ATORX Stock
  4. 0RK9 Stock
  5. Ratings Alligator Bioscience AB